This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

“I am very pleased that the clinical effect of CPL’36 has now been confirmed also for the treatment of LID dyskinesia in Parkinson’s disease,” said Celon’s CEO Maciej Wieczorek, PhD.

Dyskinesia hampers the quality of life for most Parkinson's disease patients following several years of therapy. However, the severity of L-Dopa-induced dyskinesia (LID) varies between patients ...

DBS can help Parkinson's and may also help ease TD symptoms. If other TD treatments aren't working, ask your doctor about your options. Usually, tardive dyskinesia is a long-term medical condition.

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...

Professor Karlo Malaga leads research focusing on pinpointing specific areas in the subthalamic region where deep brain ...

From family members, to friends, to beloved members of society, Parkinson’s disease impacts more than 10 million people ...

Biovail Laboratories has signed an agreement with Santhera Pharmaceuticals, entitling Biovail to the US and Canadian rights to develop and commercialize fipamezole (also known as JP-1730), for the ...

A new study led by a Bucknell biomedical engineering professor has identified key insights into optimizing deep brain stimulation for Parkinson’s disease patients to help alleviate symptoms such as ...

The Polish biotech tested two daily doses of the drug, dubbed CPL’36, in the study of 105 adults with Parkinson’s disease who had levodopa-induced dyskinesia (LID)—a term for involuntary ...